This April, Parkinson’s Awareness Month 2025, an opportunity to highlight advancements in the understanding, diagnosis, and management of Parkinson’s disease. While public awareness efforts focus on education and support for individuals and families affected by the disease, it is equally important for clinicians to stay informed of evolving clinical guidance and therapeutic developments.

In this update, we review recent clinical practice guidelines on Parkinson’s disease issued by multiple medical societies, alongside newly approved FDA treatments. This overview is intended to support evidence-based care and ensure physicians remain current on best practices in the management of Parkinson’s disease.

Part 1 - Current Parkinson's Disease Guidelines/Consensus Statements

To start, here is a listing of the current Parkinson's disease (PD) guidelines/consensus statements from the past 5 years:

Part 2 - Recent FDA Approvals

Below, are the recent medications and therapies recently approved by the FDA that we anticipate being incorporated into future US guidelines:

  • CREXONT® (carbidopa and levodopa)
    • Amneal Pharmaceuticals
    • FDA approved for PD in August 2024
    • CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromaticamino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.

  • VYALEV™ (foscarbidopa and foslevodopa)
    • AbbVie
    • FDA approved for PD in October 2025
    • VYALEV is a combination of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

  • ONAPGO (apomorphine hydrochloride)
    • Supernus Pharmaceuticals
    • FDA approved for PD in February 2025
    • ONAPGO is a dopaminergic agonist indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

  • BrainSense™ Adaptive deep brain stimulation (aDBS)
    • Medtronic
    • FDA approved for PD in February 2025
    • Adaptive technology self-adjusts the therapy and may provide motor symptom control (tremor, slowness, stiffness) throughout the day and night.

Thank you for taking the time to review the current Parkinson's disease guidelines/consensus, as well as the recent major changes and FDA approvals that have recently occurred. We value your feedback and would like to hear your suggestions for future topics to be covered in our guideline series. Please feel free to contact us with any ideas or questions you may have.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All rights reserved.